Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - What's Next?

Key Points

• Gap up: Shares gapped up pre-market, opening at $11.26 vs the prior close of $10.75 (last traded $10.78) on volume ~7,347 shares.
• Quarterly beat: The company reported Q results with EPS $0.28 vs $0.19 consensus and revenue $966.5M vs $848.4M expected, alongside a 41.82% net margin, signaling strong profitability.
• Financial strength and valuation: Shionogi shows high liquidity (current ratio 5.84), negligible leverage (debt/equity 0.01) and a market cap of $18.27B with a PE of 14.13 and PEG of 1.02.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $10.75, but opened at $11.26. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $10.78, with a volume of 7,347 shares.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. The firm's 50-day moving average price is $10.72 and its 200-day moving average price is $9.36. The stock has a market capitalization of $18.27 billion, a PE ratio of 14.13, a PEG ratio of 1.02 and a beta of 0.17.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Friday, January 30th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.19 by $0.09. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%.The company had revenue of $966.53 million during the quarter, compared to analyst estimates of $848.42 million. On average, equities analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company's product portfolio spans both established and innovative therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.